NASDAQ:XERS Xeris Biopharma (XERS) Stock Price, News & Analysis $7.89 +0.05 (+0.64%) Closing price 04:00 PM EasternExtended Trading$7.74 -0.15 (-1.89%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Xeris Biopharma Stock (NASDAQ:XERS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Xeris Biopharma alerts:Sign Up Key Stats Today's Range$7.77▼$7.9750-Day Range$4.66▼$7.9952-Week Range$2.48▼$8.03Volume1.40 million shsAverage Volume2.54 million shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice Target$7.08Consensus RatingModerate Buy Company Overview Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas. The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S. Food and Drug Administration for the treatment of severe hypoglycemia in adults and pediatric patients with diabetes. Gvoke is the first and only ready-to-use glucagon rescue product, offering rapid emergency treatment without the time-consuming reconstitution steps required by traditional glucagon kits. In addition to Gvoke, Xeris is advancing a pipeline of liquid-stable therapies, including investigational rescue treatments for seizures and other acute conditions. Founded in 2008 and headquartered in Chicago, Illinois, Xeris Biopharma operates primarily in the United States while exploring international partnerships to expand the reach of its novel drug-delivery technologies. The company is led by President and Chief Executive Officer Paul Edick, whose leadership has guided Xeris from its early research stages through the commercialization of its first product. As Xeris continues to grow its portfolio, it aims to address unmet needs across a spectrum of endocrine and neurology indications.AI Generated. May Contain Errors. Read More Xeris Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreXERS MarketRank™: Xeris Biopharma scored higher than 72% of companies evaluated by MarketBeat, and ranked 293rd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingModerate Buy Consensus RatingXeris Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageXeris Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Xeris Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Xeris Biopharma are expected to grow in the coming year, from ($0.41) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xeris Biopharma is -37.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xeris Biopharma is -37.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Xeris Biopharma's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.27% of the outstanding shares of Xeris Biopharma have been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Xeris Biopharma has recently decreased by 26.73%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXeris Biopharma does not currently pay a dividend.Dividend GrowthXeris Biopharma does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.57 Percentage of Shares Shorted8.27% of the outstanding shares of Xeris Biopharma have been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Xeris Biopharma has recently decreased by 26.73%, indicating that investor sentiment is improving significantly. News and Social Media4.0 / 5News Sentiment1.28 News SentimentXeris Biopharma has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Xeris Biopharma this week, compared to 3 articles on an average week.Search Interest19 people have searched for XERS on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.MarketBeat Follows10 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Xeris Biopharma insiders have sold 1,206.65% more of their company's stock than they have bought. Specifically, they have bought $109,500.00 in company stock and sold $1,430,777.00 in company stock.Percentage Held by InsidersOnly 4.56% of the stock of Xeris Biopharma is held by insiders.Percentage Held by Institutions42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xeris Biopharma's insider trading history. Receive XERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XERS Stock News HeadlinesJeffrey Sherman Sells 42,232 Shares of Xeris Biopharma (NASDAQ:XERS) StockAugust 30, 2025 | insidertrades.comJohn Johnson Sells 107,500 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) StockAugust 16, 2025 | insidertrades.comDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to President Trump. But many viewers missed an even more important moment in that 30-second clip. One that unmistakably singled out what Futurist Eric Fry calls "possibly the best AI investment anyone could make right now." Eric believes this little-known partner to Apple could go crazy over the next 12-24 months, potentially leaving well-known AI stocks like Nvidia, Microsoft and Google in the dust.September 4 at 2:00 AM | InvestorPlace (Ad)Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Sells $309,400.00 in StockAugust 14, 2025 | insidertrades.comXeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 RevenueAugust 29, 2025 | uk.finance.yahoo.comXeris Announces Orange Book Listing of U.S. Patent for Recorlev®August 25, 2025 | finance.yahoo.comXeris Biopharma assumed with a Buy at H.C. WainwrightAugust 12, 2025 | msn.comXeris Biopharma Holdings Second Quarter 2025 Earnings: Beats ExpectationsAugust 9, 2025 | finance.yahoo.comSee More Headlines XERS Stock Analysis - Frequently Asked Questions How have XERS shares performed this year? Xeris Biopharma's stock was trading at $3.39 at the beginning of the year. Since then, XERS stock has increased by 132.7% and is now trading at $7.89. How were Xeris Biopharma's earnings last quarter? Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) announced its quarterly earnings results on Thursday, August, 7th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The firm had revenue of $67.71 million for the quarter, compared to analysts' expectations of $64.58 million. Read the conference call transcript. When did Xeris Biopharma IPO? Xeris Biopharma (XERS) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager. Who are Xeris Biopharma's major shareholders? Xeris Biopharma's top institutional investors include Geode Capital Management LLC (2.33%), Qube Research & Technologies Ltd (1.91%), Rosalind Advisors Inc. (1.33%) and Legal & General Group Plc (1.12%). Insiders that own company stock include Paul R Edick, Kevin Mcculloch, John Patrick Shannon Jr, Beth Hecht, John Johnson and Dawn Halkuff. View institutional ownership trends. How do I buy shares of Xeris Biopharma? Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xeris Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xeris Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CymaBay Therapeutics (CBAY) and CrowdStrike (CRWD). Company Calendar Last Earnings8/07/2025Today9/04/2025Next Earnings (Estimated)11/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XERS CIK1867096 Webwww.xerispharma.com Phone(844) 445-5704FaxN/AEmployees290Year FoundedN/APrice Target and Rating Average Price Target for Xeris Biopharma$7.08 High Price Target$10.00 Low Price Target$4.00 Potential Upside/Downside-10.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$54.84 million Net Margins-13.01% Pretax Margin-14.36% Return on EquityN/A Return on Assets-8.00% Debt Debt-to-Equity RatioN/A Current Ratio1.95 Quick Ratio1.24 Sales & Book Value Annual Sales$203.07 million Price / Sales6.28 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-65.79Miscellaneous Outstanding Shares161,480,000Free Float154,117,000Market Cap$1.27 billion OptionableOptionable Beta0.13 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:XERS) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.